Pre-clinical studies have demonstrated that certain immunomodulatory antibodies, such as those targeting GITR (26), OX40 (27), and CTLA-4 (28, 29), relied on Fc-dependent depletion of intra-tumoral Tregs for optimal anti-tumor activity. Here, CTLA4 is linked to neoplasm.